SAB Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SABS Nasdaq 2834 www.sabbiotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SAB Biotherapeutics, Inc.

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - May 9th, 2025 7:00 am
SAB BIO Reports Full Year 2024 Operating and Financial Results - Mar 31st, 2025 5:32 am
SAB BIO to Participate in Upcoming Investor Conferences - Jan 31st, 2025 5:00 am
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Jan 28th, 2025 5:00 am
3 Promising US Penny Stocks With At Least $20M Market Cap - Jan 27th, 2025 1:04 pm
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - Jan 23rd, 2025 5:00 am
SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider - Dec 23rd, 2024 6:04 am
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts - Nov 15th, 2024 7:50 am
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) - Nov 9th, 2024 7:40 am
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - Nov 6th, 2024 3:05 pm
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - Oct 31st, 2024 5:00 am
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Sep 23rd, 2024 8:53 am
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - Sep 13th, 2024 5:00 am
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - Sep 9th, 2024 5:00 am
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - Sep 4th, 2024 5:05 am
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - Aug 8th, 2024 3:51 pm
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - Aug 5th, 2024 5:30 am
SAB BIO Appoints Lucy To as Chief Financial Officer - Jul 31st, 2024 5:30 am